Insider Selling: Artivion (NYSE:AORT) SVP Sells 1,668 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 1,668 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total value of $59,530.92. Following the transaction, the senior vice president directly owned 152,203 shares in the company, valued at $5,432,125.07. This trade represents a 1.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Artivion Trading Up 0.9%

Shares of NYSE AORT traded up $0.31 during midday trading on Wednesday, reaching $35.66. The company had a trading volume of 300,261 shares, compared to its average volume of 399,410. The stock has a market cap of $1.71 billion, a PE ratio of 178.32 and a beta of 1.59. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The firm’s fifty day moving average price is $42.51 and its 200-day moving average price is $43.14. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AORT. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Canaccord Genuity Group dropped their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Finally, Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently bought and sold shares of AORT. Aster Capital Management DIFC Ltd boosted its position in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion in the 3rd quarter worth approximately $27,000. Larson Financial Group LLC lifted its stake in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares during the period. USA Financial Formulas boosted its position in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.